6001 International randomised phase III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) in first line treatment of metastatic colorectal cancer (mCRC): final results of the AGITG MAX trial
2009 ◽
Vol 7
(2)
◽
pp. 321
◽
Keyword(s):
Keyword(s):
2005 ◽
Vol 23
(16_suppl)
◽
pp. 3525-3525
◽
Keyword(s):
2016 ◽
Vol 34
(15_suppl)
◽
pp. TPS3625-TPS3625
◽
Keyword(s):
Keyword(s):
Keyword(s):
2005 ◽
Vol 3
(2)
◽
pp. 179-180
◽
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):